Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers.
Marked synergy between the antirhinoviral effect of rHuIFN alpha and enviroxime has been observed in vitro but an attempt to demonstrate it in volunteers was unsuccessful. The sub-optimal intranasal dose of rHuIFN alpha (0.18 Mu four times daily for 4 1/4 days) used prophylactically in the trial did reduce the severity of colds induced by RV9 and 14, but the difference did not reach statistical significance and was not enhanced by the administration of enviroxime (0.28 mg six times daily for six days). The main reason for failure is thought to be the rapid removal of enviroxime from the nose when given intranasally.
Higgins
P G
PG
MRC Common Cold Unit, Harvard Hospital, Salisbury, Wiltshire, U.K.
Barrow
G I
GI
al-Nakib
W
W
Tyrrell
D A
DA
DeLong
D C
DC
Lenox-Smith
I
I
D000293:Adolescent; D000328:Adult; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D003139:Common Cold / Q000517:prevention & control / Q000628:therapy*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010091:Oximes; D013449:Sulfonamides
D001562:Benzimidazoles; D007370:Interferon Type I; D010091:Oximes; D013449:Sulfonamides; C021595:viroxime